An international commission, including our Jeffrey Kahn, has been convened by the NAM, NAS, and the Royal Society with the participation of science & medical academies around the world, to develop a framework for scientists, clinicians, and regulatory authorities to consider when assessing potential clinical applications of human germline genome editing

Quick Read

The draft rules mean that anyone who manipulates human genes in adults or embryos is responsible for adverse outcomes

Quick Read

A panel of government-appointed experts in Germany agreed unanimously that the human germline “is not inviolable,” rejecting one objection to using genome editing technologies such as CRISPR to make heritable changes in the DNA of human embryos, sperm, or eggs

Quick Read

If you take genes from another kind of plant, or bacteria, and insert them into a crop like soybeans, the result is considered a GMO. You need government approval to sell a new GMO. If you just take a snippet out of a gene without inserting anything new, though, the product falls into a gray area

Quick Read

If all goes as planned, the first clinical trial in the United States testing CRISPR against cancer by altering the DNA of tumor cells inside patients could begin recruiting participants next year, the scientist leading the effort told STAT

Quick Read

Updated regulations allow scientists to use some genome-editing techniques in plants and animals without government approval

Quick Read

But the practical challenges of breeding and maintaining unconventional lab animals persist

Quick Read

“2019 is the year when the training wheels come off and the world gets to see what CRISPR can really do for the world in the most positive sense,” says Fyodor Urnov, a gene-editing scientist at the Altius Institute for Biomedical Sciences in Seattle and the University of California, Berkeley

Quick Read